March 3, 2022 — Median Technologies announced that the company has filed a 513(g) submission on Feb. 17, 2022, to the United States Food and Drug Administration (FDA) for its iBiopsy Lung Cancer Screening (LCS) AI/ML technology-based end-to-end CADe/CADx Software as Medical Device (SaMD).

March 3, 2022 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) deplores the recent invasion of Ukraine that has resulted in the death and injury of a large number of innocent men, women, and children—a horrifying contrast to our work to save lives and improve patient care.

March 2, 2022 — Analyzing breast-cancer tumors with artificial intelligence has the potential to improve healthcare efficiency and outcomes. But doctors should proceed cautiously, because similar technological leaps previously led to higher rates of false-positive tests and over-treatment.

March 2, 2022 — Artificial intelligence (AI), deep learning (DL), and machine learning (ML) have transformed many industries and areas of science. Now, these tools are being applied to address the challenges of cancer biomarker discovery, where the analysis of vast amounts of imaging and molecular data is beyond the ability of traditional statistical analyses and tools.

March 2, 2022 — Gleamer, a French medtech company pioneering the use of artificial intelligence technology in the practice of radiology, announced today that the United States Food and Drug Administration has cleared its BoneView AI software for use by U.S. healthcare specialists to aid in diagnosing fractures and traumatic injuries on X-rays.

March 1, 2022 — RSIP Vision, an experienced leader in driving innovation for medical imaging through advanced AI and computer vision solutions, announced a new tool for

March 1, 2022 — With more than $12 million in new funding from the National Institutes of Health (NIH), the Abramson Cancer Center at the University of Pennsylvania will build on its preclinical research of an emerging form of radiation that provides ultra-fast doses—of under a second, compared to several minutes with conventional radiation—and shows promise of greater protection of normal tissue, thereby minimizing toxic effects to the body.

March 1, 2022 — Today, the U.S. Food and Drug Administration issued three final guidances to industry regarding cancer clinical trials that parallel the goals of President Biden’s recently announced effort to renew and build upon his 2016 Cancer Moonshot initiative to facilitate continued advancement in cancer prevention, detection, research and patient care.

Medical imaging and contrast use have become an integral part of the diagnostic process to determine the best individually tailored treatments. This, in turn, has driven demand for innovative injector systems that offer greater control, more safety features, dependable performance and ease of use.

February 28, 2022 — Core Sound Imaging, a leader in cloud-based clinical imaging workflow management, announced the 6.0 release of the company’s innovative cloud-based medical image storage and reporting solution,

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now